Kenneth Perego, MD
Urology · Natchitoches, LANPI 1790758829
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Pfizer at 25.6% of the total. Among urology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $62.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Boston Scientific$3K
- Telix Pharmaceuticals$2K
- Intuitive Surgical$2K
- Johnson & Johnson$1K
- Axonics, Inc.$1K
- plus $4K from 31 others
What the payments were for
- Consulting fees$3,34019%
- Travel & lodging$4,97828%
- Food & beverage$7,52142%
- Education$2,16512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $4,600 |
| Boston Scientific | 12 | $3,148 |
| Telix Pharmaceuticals | 9 | $1,908 |
| Intuitive Surgical | 4 | $1,777 |
| Johnson & Johnson | 66 | $1,497 |
| Axonics, Inc. | 23 | $1,274 |
| Astellas Pharma US Inc | 25 | $776 |
| Endo Pharmaceuticals Inc. | 38 | $529 |
| Bayer | 18 | $340 |
| Endo USA, Inc. | 17 | $320 |
| Bioprotect Medical, Inc. | 1 | $254 |
| AbbVie(2 entities) | 13 | $228 |
| Neotract Inc. | 7 | $200 |
| Palette Life Sciences, Inc. | 1 | $143 |
| AstraZeneca | 7 | $122 |
| Coloplast | 3 | $111 |
| Organogenesis Inc. | 1 | $100 |
| Janssen Scientific Affairs, LLC | 2 | $99 |
| Progenics Pharmaceuticals, Inc. | 3 | $93 |
| Photocure Inc | 1 | $54 |
| EDAP Technomed Inc | 1 | $50 |
| Merck | 3 | $47 |
| Myovant Sciences Inc. | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 2 | $32 |
| Tolmar Pharmaceuticals, Inc. | 2 | $30 |
| Cook Medical LLC | 1 | $29 |
| Medtronic | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Immunitybio, Inc. | 1 | $26 |
| Procept Biorobotics Corporation | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Eagle Pharmaceuticals, Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$4,394
- SPACEOAR VUE$3,105
- ILLUCCIX$1,607
- DAVINCI XI$1,500
- Bulkamid$265
- Axonics$260
- BIOPROTECT BALLOON IMPLANT SYSTEM$254
- Da Vinci Surgical System$254
- Erleada$143
- XTANDI$112
- Apligraf$100
- Dermagraft$100
- Puraply/Affinity/NuTech$100
How this compares
$18,004 in reported general payments places this provider in the 90th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 66 | $968,213 |
| NubeqaDarolutamide | 38 | $512,292 |
| Abiraterone Acetate | 43 | $287,162 |
| MyrbetriqMirabegron | 49 | $28,815 |
| GemtesaVibegron | 35 | $19,809 |
| Tamsulosin Hcl | 400 | $4,560 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 74 | $1,972 |
| Estradiol | 19 | $1,317 |
| Finasteride | 37 | $1,055 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $778 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 25 | $718 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 37 | $564 |
| Prednisone | 38 | $350 |
| CefuroximeCefuroxime Axetil | 29 | $331 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,497 | $968,21366 claims |
| BayerNubeqa | $340 | $512,29238 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $99 | $287,16243 claims |
| Astellas Pharma US IncMyrbetriq | $776 | $28,81549 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $27 | $19,80935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 199 urology providers in Louisiana.
Other urology in Natchitoches
- Richard VanlangendonckNew Orleans$289K
- Gerard HenryBossier City$256K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Sunil PurohitCovington$99K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Kevin HebertShreveport$54K
- Jorge CasoNew Orleans$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.